Clinical Trial Search

Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…

Primary: Safety and Tolerability — 3; 7 Participants with a TEAE

Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters

Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: Sensitivity for 100 HEP/mL — 75; 0 positive reaction

Primary: Visual Analog Scale (VAS) — 3.35 units on a scale

Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980

Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score

Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale

Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale

Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants

Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale

Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Classification of Test Site Region Reaction — 1247; 163; 1126; 284 Skin Patch Interpretations

Primary: Wheal Response — 6.8 mm

Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale

Primary: Number of Patients With Treatment Emergent Adverse Events (TEAEs) — 3; 6 Participants

Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…

Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants

Primary: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 — 8.4567; 4.2618 F/mm^2

Primary: Duration of Urticaria Until Remission Since Chronic Urticaria Was Diagnosed. — 18.5; 54; 67.7 percentage of participants

Primary: Proportion of Subjects With Allodynia During a Migraine Attack — 15 participants

Primary: Dermal Reactions — 46; 97; 151; 6 Participants

Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001